How about the export of Chinese herbal medicines in China?

The EU Law on Traditional Medicine was promulgated and came into effect on April 30th this year. This law is the first time that the European Union has legally granted legal status to Chinese patent medicines that meet the relevant requirements, which has a vital impact on the long-term development of traditional Chinese medicine manufacturers and Chinese patent medicines in China.

Although during the transitional period of the Bill, proprietary Chinese medicines still have no status as medicines, they are still sold in their present form. However, in order to successfully land in Europe as soon as possible, Chinese patent medicine production and trading enterprises in Beijing have been warming up, increasing export volume and actively preparing for market development since the bill came into effect.

According to the statistics of Beijing Customs, from June 5438 to April this year, 8.6 tons of Beijing proprietary Chinese medicines were exported to the European Union, with a value of US$ 33,000, down by 2.9% and 40% respectively compared with the same period last year. In the first half year (May-June, 65,438+1October), the export volume reached 20 1 ton and165,000 US dollars respectively, increasing by 59.7% and 87.5% respectively. Due to the strong pull from May to June in 10, in June1-June 17.2 percentage points, the export of Chinese patent medicines to the EU increased by 33.9% and 38.5% respectively, exceeding the overall increase of Beijing's export of Chinese patent medicines1kloc-0/.7 and/kl.

It can be seen that the promulgation of the European Union's Traditional Medicine Law has played a strong role in promoting the recent sharp increase in the sales of Beijing proprietary Chinese medicines in EU countries. Once the status of Chinese patent medicine in the EU is confirmed, the price of Chinese patent medicine in the EU market will rise sharply, which undoubtedly stimulates the confidence of pharmaceutical manufacturing industry to enter the European market.

Although the export volume of Beijing proprietary Chinese medicines to EU countries has increased rapidly in recent years, the EU's share in the total export volume of Beijing proprietary Chinese medicines is still small. According to the data, from 1 to 1 this year, Beijing exported 867 tons of Chinese patent medicines to the world, with a value of16.36 million US dollars, of which EU countries only accounted for 3.3%, 1.2%. Asia is still the largest export market, with exports of 637 tons, up 6.3%, accounting for 74% of the total. It is still difficult for Chinese patent medicines to go to Europe and meet the requirements stipulated in the Law on Traditional Medicine:

First, EU countries lack the cultural background of TCM. Unlike Hongkong, Japan, South Korea and other countries or regions, EU countries are deeply influenced by China's traditional culture. It is only because more and more China people are working and studying in EU countries that the use of Chinese patent medicines has been brought to Europe. Therefore, the development foundation of Chinese medicine in the EU is weak.

Second, it is difficult for Chinese patent medicines to gain "legal" status generally at present. Due to the influence of modern western medical background, Chinese patent medicine manufacturers can successfully register their products in Europe and obtain the legal "identity" of drugs only after passing the examination of European GMP (good manufacturing practice). Otherwise, it can only appear in the form of health care products, food or complementary food. For some small and medium-sized manufacturers engaged in Chinese patent medicine export trade in Beijing, it is still difficult to pass the EU GMP review. Therefore, manufacturers prefer to choose countries or regions with less export constraints as the main export targets.

Third, it is difficult to form the EU standard drug test report of compound Chinese patent medicine. Chinese patent medicines are mostly compound traditional Chinese medicines, which are often made up of more than a dozen components and then processed by "detoxification and synergy". It is almost impossible to quantify the curative effect of each component and form a drug test report with scientific experiments of western medicine, which makes compound Chinese patent medicine enter the European Union again.

Take Tongrentang Group, a large Chinese patent medicine exporter in Beijing, as an example. Although it is also vigorously developing simple Chinese patent medicines, it still mainly exports compound Chinese patent medicines as a whole. Due to the drug inspection system in the EU, it is difficult for businesses to shift their export focus to the EU in a short time, thus making the export share of Beijing proprietary Chinese medicines to the EU still very small.

Fourthly, international competition should restrain the export growth of Chinese patent medicines. At present, Chinese patent medicines have spread all over the world. While recognizing the efficacy of Chinese patent medicine, western countries have also seen the rich profits of Chinese patent medicine. Therefore, some foreign pharmaceutical companies began to invest in the research and development of proprietary Chinese medicines and applied for patents internationally, which brought a great impact on the research and development of proprietary Chinese medicines in China and further curbed the export of proprietary Chinese medicines.

Business newspaper link:

This year, the export of traditional Chinese medicine in China can reach 700 million US dollars.

According to the news from the Chinese Medicine Department of China Chamber of Commerce for Import and Export of Medicines and Health Products, since 2004, the export of Chinese medicine in China has increased rapidly. In the first three quarters, the total export of traditional Chinese medicine exceeded US$ 500 million, up by 18.23% year-on-year, which was the fastest growing period since the Asian financial crisis.

According to Liu, director of the Chinese Medicine Department of the Medical Insurance Chamber of Commerce, in the first three quarters of 2004, the export of deep-processed and high value-added Chinese medicines grew well, among which the export of plant extracts grew the fastest, reaching 654.38+62 billion US dollars, up 35.9 1% year-on-year, accounting for 365.438+0.76% of the total export of Chinese medicines. The export of Chinese herbal medicines was $25 1 billion, a year-on-year increase of13.77%; The export of Chinese patent medicines was US$ 97.04 million, a year-on-year increase of 6%. Asia is still the largest market for China's Chinese medicine exports, and China's Chinese medicine exports to Asia, North America and Europe account for 66.08%, 14.56% and 14.46% of China's total Chinese medicine exports respectively. Exports to South America, Africa and Oceania account for only 4.9% of China's total Chinese medicine exports.

Based on the analysis of the export situation of plant extracts, Liu believes that the sustained and rapid growth of the demand for plant medicines in the world market, the growth of Japanese and Korean Chinese medicine markets and the forward movement of production lines are the two main reasons for the rapid growth of China's export of plant extracts. In addition, the export of plant extracts from China to all continents has also increased significantly. The United States is still the largest export market of plant extracts in China. From June to September, the export to the United States was 50.36 million US dollars, up 65.438+08.54% year-on-year, accounting for 365.438+0. 12% of the total export of plant extracts in China. The export growth rate of plant extracts from China to Europe, South America and Oceania is over 40%. The absolute value of China's export of plant extracts to Africa is still small, with the export value of US$ 6,543,800+0,370 in the first nine months, up by 28.33% year-on-year. Exports to North America were $565,438 +0.97 million, a year-on-year increase of 19. 14%.

The export performance of proprietary Chinese medicines is still not very good, and one of the important factors is that the implementation of the EU traditional drug registration directive has had a certain impact on the export of proprietary Chinese medicines. From June 5438 to September, China exported 8.02 million US dollars of Chinese patent medicines to Europe, down 13.34% year-on-year. China's export of proprietary Chinese medicines to other markets has increased to a certain extent. Asia is the main market for China's export of proprietary Chinese medicines. From June to September, exports to Asia reached 70.66 million US dollars, up 3.95% year-on-year, accounting for 72.82% of China's total exports of proprietary Chinese medicines. North America is the second largest market for the export of proprietary Chinese medicines. From June 5438 to September, the export to North America reached 85 1 10,000 US dollars, up 1 1.7 1% year-on-year. Although the absolute value of exports to Africa, Oceania and South America is small, they have all experienced rapid growth.

From the analysis of countries and regions, China's exports of Chinese patent medicines to Hong Kong, the largest export market, grew rapidly due to the initial achievements in the construction of Hong Kong's "Chinese medicine port" and the pull of various factors, with exports of US$ 33.42 million from/kloc-0 to September, up by 3.02% year-on-year. The export of proprietary Chinese medicines to Japan ranked second, from 1 USD to * * *16.99 million USD in September, with a year-on-year increase of 1.4 1%.

The export situation of Chinese herbal medicines is good, with the total export volume reaching 167574 tons in the first nine months, up by 3.28% year-on-year; Total export growth13.77%; The average unit price increased from $0/400 per ton to $0/500 per ton, with an increase of 10. 15%. Asia is still the main market for Chinese herbal medicine exports. From June 5438 to September, the export to Asia was US$ 204 million, up by 13.62% year-on-year, accounting for 8 1.86% of the total export of Chinese herbal medicines. Among them, exports to Hong Kong exceeded those to Japan, with an export value of US$ 6,765,438+200,000, up 59.70% year-on-year, accounting for 26.77% of the total exports of Chinese herbal medicines. The export to Japan was 58.23 million US dollars, up 3.35% year-on-year, accounting for 23.2 1% of the total export of Chinese herbal medicines.